Abattis Bioceuticals Corp. — Wednesday, November 21st 2018 at 1:00pm UTC
VANCOUVER, British Columbia, Nov. 21, 2018 (GLOBE NEWSWIRE) — Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce the appointment of Ingredient Identity LLC (“Ingredient Identity”), a Canadian and US regulatory and compliance agency, to assist the Company’s wholly-owned subsidiary, Vergence Naturals Ltd. (“Vergence Naturals”), with their ongoing Canadian and US regulatory compliance program.
“Regulatory compliance is a cornerstone objective for Vergence Naturals, or any nutraceutical business,” stated Rob Abenante, President and CEO of Vergence Naturals.
“Navigating the ever-changing landscape of allowable claims and statements can be tricky, but adding international claims to the mix makes it even more difficult to keep up without professional representation. Ingredient Identity are the nutraceutical industry experts in compliance,” added Mr. Abenante.
“It is critically important to perform high-level regulatory consulting, strategic planning and due diligence for projects and to effectively plan for growth or mitigate high risk legal and regulatory matters,” stated Jim Lassiter, CEO of Ingredient Identity. “We provide the development and review of content for labeling, packaging, website copy, label claims, claims substantiation and television commercial or radio scripts to ensure compliance with the GMPs, FDA, FTC or other regulatory agencies governing such products in the global marketplace.”
“One example of the difficulty of international regulatory compliance with respect to Natural Health Products is that Canada allows for turmeric – a phytocannabinoid spice – to be labelled as an ‘anti-inflammatory,’ however, no herbal supplement sold in the USA may use that term,” commented Brandon Griffin, President and Co-Founder of Ingredient Identity.
“Imagine the chaos created by this type of legal ‘tug-of-war’,” commented Dr. Brazos Minshew, head of the Medical Advisory Board for Vergence Naturals and Abattis.
“You can see why Vergence Naturals needs top-tier regulatory compliance support as we develop our International markets. 2018 will end in a flurry of sales activity for Vergence Naturals surrounding the phytocannabinoid pain-reliever, Comfort! and Comfort Extra-Strength! Our relationship with Ingredient Identity will help us properly plan these product launches, while avoiding the legal mine-field associated with Canadian / US political animas,” added Dr. Minshew.
Chief Operating Officer and Role Changes
This Company is also pleased to announce the appointment of Patrick Mitchell as Chief Operating Officer, replacing Kent McParland. Mr. Mitchell, a supply chain management professional, joins Abattis following 15 years in the private sector specializing in the food, beverage, nutraceutical, dietary supplement and fertilizer industries. His expertise in project management and corporate operations, both domestic and abroad, will be an added asset as Abattis continues to grow.
Mr. McParland will continue to serve in the role as Chief Financial Officer for the Company going forward, with an increased focus on the positioning and alignment of Abattis for future success.
“As we continue to grow and develop as a company within the newly legalized cannabis space in Canada, we are excited to be adding Patrick to our executive team,” stated Mr. Abenante. “Patrick brings a myriad of operational skills and real-world experience that will be a major force behind the continued success and growth in Abattis,” added Mr. Abenante.
As Abattis has been developing its assets over the past 10 years, the Company is primed and ready to start the development of such assets alongside the furthering of its business in the near future. With a specific focus on shareholder value and revenue generation, Abattis is confident that its marketing and promotional efforts going forward will not only aid in raising investor awareness of the Company’s offerings, but will also increase shareholder sentiment as information is made public on a more regular basis.
To continue to build market awareness, the Company has retained Link Media LLC (“Link”), a communications and market awareness provider, to author and distribute a series of independent articles on the Company (the “Services”). Each article will be reviewed and approved by the Company prior to release to ensure each articles’ contents are consistent with the Company’s vision and that information contained therein is consistent with the Company’s public disclosure. As compensation for Link providing the Services, Link will be paid USD $175,000. To the best of the Company’s knowledge, Link does not own any of the Company’s securities and, throughout the duration of the engagement, will maintain an arm’s length relationship.
“We are very excited to be extending our marketing efforts in the upcoming months, as operations ramp up in anticipation of our launch of our first cannabinoid product” stated Rob Abenante, President and CEO of Abattis.
“We anticipate our strongest quarters in both our Vergence Naturals and Abattis Vaporizers divisions as we continue to develop our late-stage ACMPR LP application on Gabriola Island through our wholly-owned subsidiary, Gabriola Green Farms. The Company also plans to continue moving forward with its joint-ventures and continues to seek value-add acquisitions to build shareholder growth” added Mr. Abenante.
About Abattis Bioceuticals Corp.
Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols and adheres to applicable laws of Canada and foreign jurisdictions.
ON BEHALF OF THE BOARD,
ABATTIS BIOCEUTICALS CORP,
Robert Abenante, President & CEO
For more information, please visit the Company’s website at: www.abattis.com
For inquiries please contact (808) 650-3007 or at firstname.lastname@example.org.
Abattis IR is managed by Canada One Communications Inc.
About Canada One Communications Inc.
Canada One Communications Inc. (“Canada One”) is a full-service Investor Relations and Marketing company that focuses on both private and public sectors within the Canadian markets. Canada One offers timely responses to all investor inquiries over several mediums and effective, thorough market awareness programs that are specifically designed to maximize exposure and bring value to shareholders. Canada One’s dedicated and experienced team strives to promote client information to the public and educate potential investors on the various developments of its clients. From basic phone-call and email investor correspondence, to full-scale comprehensive marketing packages which includes industry analysis, website development, corporate videos and other marketing programs, Canada One provides a full suite of services that are fully compliant with Canadian securities regulations. Canada One is driven by an uncompromising dedication to provide publicly listed and private companies with across-the-board investor relations and marketing solutions, directly translating these services into organic growth and increased market value of its valued clients.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words including but not exclusive to “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “intends”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding the success of the marketing and promotion of the Company going forward and the anticipated success of the Company in the cannabis market. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Additional risk factors are included in the Company’s Management’s Discussion and Analysis, available under the Company’s profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.